Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Foghorn Therapeutics (FHTX) Leases (2020 - 2025)

Foghorn Therapeutics has reported Leases over the past 6 years, most recently at $30.9 million for Q4 2025.

  • Quarterly results put Leases at $30.9 million for Q4 2025, up 36.69% from a year ago — trailing twelve months through Dec 2025 was $30.9 million (up 36.69% YoY), and the annual figure for FY2025 was $30.9 million, up 36.69%.
  • Leases for Q4 2025 was $30.9 million at Foghorn Therapeutics, up from $10.2 million in the prior quarter.
  • Over the last five years, Leases for FHTX hit a ceiling of $40.7 million in Q2 2021 and a floor of $400000.0 in Q1 2021.
  • Median Leases over the past 5 years was $31.2 million (2023), compared with a mean of $28.1 million.
  • Biggest five-year swings in Leases: skyrocketed 9250.5% in 2022 and later crashed 57.71% in 2025.
  • Foghorn Therapeutics' Leases stood at $38.5 million in 2021, then fell by 11.5% to $34.1 million in 2022, then dropped by 12.12% to $30.0 million in 2023, then fell by 24.42% to $22.6 million in 2024, then surged by 36.69% to $30.9 million in 2025.
  • The last three reported values for Leases were $30.9 million (Q4 2025), $10.2 million (Q3 2025), and $10.9 million (Q2 2025) per Business Quant data.